What is the core product Sensotrend is building?

Sensotrend is building a cross-platform data aggregation dashboard for diabetes management. As shown on Slide 3, the software pulls data from various third-party hardware devices—including activity trackers like Jawbone, glucose meters like Accu-Chek, and insulin pumps—and presents them in a unified interface accessible via web, tablet, and mobile devices.

How does the team demonstrate founder-market fit?

The team slide (Slide 5) highlights that the lead founder, Mikael, has lived with Type 1 diabetes for 15 years and has 16 years of software experience. This combination of personal patient experience and technical proficiency is a strong signal to investors that the product is built to solve real-world user pain points.

What are the key milestones on the Sensotrend roadmap?

According to Slide 4, the company planned a launch in Finland in late 2014, followed by an international launch in 2015. The roadmap includes clinical trials in 2016, achieving Medical Device Certification in 2017, and moving into advanced data analytics by 2018.

What market data does Sensotrend use to justify the opportunity?

Sensotrend uses two primary sources: the IDF Diabetes Atlas 2013 for global healthcare expenditure (Slide 7) and research2guidance for the growth of the diabetes app market (Slide 8). The latter predicts the market will grow from $4.1 million to $465 million over a five-year period.

What is missing from this pitch deck?

The deck is notably missing a business model slide explaining how they charge for the service (B2B vs. B2C). It also lacks a 'The Ask' slide, meaning there is no information on how much capital they are raising or how they intend to use the funds. Finally, there is no mention of existing competitors or their specific competitive advantage.

Sensotrend Pitch Deck (2013): 15-Slide Breakdown

See all 15 slides of the Sensotrend pitch deck — a 2013 deck — with a slide-by-slide teardown of what the deck does well and where it falls short.

Sensotrend’s pitch deck, presented at a Startup Sauna Demo Day, addresses the fragmented landscape of diabetes management. The deck highlights the 'Old Way' of manual logging (Slide 2) and proposes a unified dashboard that aggregates data from insulin pumps, glucose monitors, and activity trackers (Slide 3). The team leverages significant domain expertise, including a founder with 15 years of personal experience with Type 1 diabetes (Slide 5). While the deck successfully establishes the market scale using IDF Diabetes Atlas 2013 data (Slide 7) and projects a growth path toward medical device…

Key takeaways

The problem is framed as a transition from 'Manual Entry' on paper to automated digital tracking (Slide 2).
The solution acts as a middleware layer, connecting hardware like Jawbone and Accu-Chek to a unified dashboard (Slide 3).
The roadmap outlines a five-year plan from launch in Finland (2014) to medical device certification (2017) and advanced data analytics (2018) (Slide 4).
The team possesses deep founder-market fit, with Mikael citing 15 years as a Type 1 diabetic and 16 years as a software professional (Slide 5).
The company is supported by a medical advisory board including three MDs from the Finnish Diabetes Association and various university hospitals (Slide 5).
Market size is quantified globally, citing $263B in North America and $147B in Europe/Russia according to the 2013 Diabetes Atlas (Slide 7).
Growth projections suggest a market expansion from $4.1M in 2013 to $465M by 2018 based on research2guidance data (Slide 8).
The deck is missing a specific funding ask, valuation, or detailed breakdown of the business model.

Sensotrend Pitch Deck Analysis

The Sensotrend deck, presented at a Startup Sauna Demo Day, is a classic example of a vision-led healthcare pitch. It focuses heavily on the 'why' and the 'who,' leveraging the personal story of the founders to validate the 'what.' While the deck is visually clean and follows a logical progression, it leaves several critical business questions unanswered, which is common for early-stage demo day presentations intended to spark initial interest rather than close a round on the spot.

Slide 1: Title Slide

The deck opens with the Sensotrend logo and the tagline "...making sense of diabetes trends." The branding is minimalist, using a blue circle (a common symbol in diabetes awareness) to replace the 'o' in Sensotrend. This immediately identifies the niche and the value proposition: data interpretation.

Slide 2: The Problem - The Old Way

Slide 2 uses a full-bleed background image of a spiral notebook and a pen with the text "THE OLD WAY: MANUAL ENTRY." This is a powerful, albeit simple, way to illustrate the friction in current diabetes management. It highlights that the status quo is analog, prone to error, and burdensome for the patient. By framing the problem this way, the solution becomes an obvious necessity rather than a luxury.

Slide 3: The Solution - Data Aggregation

This slide visualizes the product's architecture. It shows four categories of external inputs: a smartphone, a Jawbone activity tracker, an Accu-Chek glucose meter, and a Medtronic/CareLink insulin pump system. Arrows point from these devices toward the Sensotrend logo, which then feeds into a multi-device dashboard (laptop, tablet, and smartphone). This slide clearly defines Sensotrend as a software-only aggregator that harmonizes data from a fragmented hardware market.

Slide 4: Roadmap and Milestones

2014: Launch in Finland. · 2015: International Launch. · 2016: Clinical trials. · 2017: Medical Device Certification. · 2018: Data analytics.

Analysis: The inclusion of "Medical Device Certification" in 2017 is a critical detail. It suggests the company understands the regulatory hurdles of MedTech. However, the five-year span is quite long for a startup deck, and investors might question the capital requirements to sustain the company until the 2018 analytics phase.

Slide 5: The Team and Advisors

This is arguably the strongest slide in the deck. It lists three core team members: Mikael (Type 1 diabetic for 15 years, software pro for 16 years), Assi (Healthcare PR, marketing, and sales), and Jere (Software pro and mobile app startup experience). The combination of personal lived experience and professional tenure is highly persuasive. Below the core team, they list three Medical Doctors (Pirjo Ilanne-Parikka, Jorma Lahtela, and Päivi Hannula) associated with major Finnish medical institutions. This provides the necessary clinical credibility for a health-focused startup.

Slide 6: Contact Information

A mid-deck contact slide featuring Mikael Rinnetmäki’s email, phone number, and Twitter handle. While usually reserved for the end, placing it here suggests this might have been the final slide of a shorter version of the pitch, or a transition point in the presentation.

Slide 7: Global Market Opportunity

Citing the "IDF: Diabetes Atlas 2013," this slide uses a map to show global healthcare spending related to diabetes. The figures are massive: $263B in North America, $147B in Europe, and $88B in the Western Pacific. While these numbers represent the total cost of the disease rather than the addressable market for a software app, they serve to illustrate the scale of the problem Sensotrend is tackling.

Slide 8: Market Growth and Penetration

This slide provides more granular data from "research2guidance." It shows a bar chart of the "Addressable market" and "Diabetes app users," with a red line indicating "Penetration." The slide notes a jump from $4.1 M in 2013 to $465 M in 2018. This 100x growth projection in the specific niche of diabetes apps is much more relevant to an investor than the total healthcare spend shown on the previous slide.

What Works in the Sensotrend Deck

1. Founder-Market Fit: The team slide (Slide 5) is excellent. In health tech, having a founder who is also a patient (Mikael) provides a level of empathy and insight that cannot be manufactured. Combining that with 16 years of software experience mitigates the risk of technical execution.

2. Clear Problem/Solution Gap: The transition from Slide 2 (the notebook) to Slide 3 (the automated dashboard) is a textbook example of how to present a digital transformation play. It makes the value proposition—saving time and increasing accuracy—immediately apparent.

3. Regulatory Awareness: Many health startups fail to account for the time and cost of certification. By explicitly listing "Medical Device Certification" on their roadmap (Slide 4), Sensotrend signals to investors that they are not just building a "wellness app," but a serious clinical tool.

What is Missing from the Sensotrend Deck

1. The Business Model: There is no mention of how Sensotrend makes money. Is it a subscription for patients? A licensing fee for clinics? A data play for pharmaceutical companies? Without this, it is impossible to evaluate the financial viability of the company.

2. Competitive Landscape: The diabetes tech space is crowded. Companies like Glooko, Dexcom, and even Apple/Google were making moves in health data during this period. Sensotrend does not explain why their dashboard is superior to the native apps provided by the hardware manufacturers (like the CareLink system shown on Slide 3).

3. The Ask: A pitch deck is a fundraising tool. This deck fails to state how much money they are looking for, what the terms are, or what specific milestones the new capital will unlock. Even in a demo day setting, a "we are raising X amount" bullet point is standard.

4. Unit Economics: While the market growth is shown (Slide 8), there is no data on Customer Acquisition Cost (CAC) or Lifetime Value (LTV). For a mobile-first application, these metrics are vital for understanding if the business can scale profitably.

Founder's Guide: What to Copy

Use Visual Analogies for the Problem: The use of the notebook in Slide 2 is a great way to evoke the "pain" of the current process without using a wall of text. Founders should look for a single image that represents the inefficiency they are solving.

Highlight Clinical Advisors: If you are in a regulated space, your advisors are as important as your founders. Sensotrend’s inclusion of MDs from the Finnish Diabetes Association (Slide 5) adds immediate weight to their claims.

Cite Reputable Sources: Using the IDF Diabetes Atlas and research2guidance (Slides 7 and 8) gives the market data an air of objectivity. Always use third-party data to validate the size of your opportunity rather than making internal guesses.

Final Thoughts

Sensotrend’s deck is a strong "vision" pitch. It identifies a massive global problem, presents a logical software solution, and introduces a team that is uniquely qualified to build it. However, as a "fundraising" pitch, it is incomplete. To move to a term sheet, the founders would need to supplement these slides with a deep dive into their revenue model, their competitive moat, and their specific capital requirements. The roadmap is ambitious, but the lack of financial data makes it difficult to assess the risk-to-reward ratio for a potential investor.

Frequently asked questions

What is the core product Sensotrend is building?: Sensotrend is building a cross-platform data aggregation dashboard for diabetes management. As shown on Slide 3, the software pulls data from various third-party hardware devices—including activity trackers like Jawbone, glucose meters like Accu-Chek, and insulin pumps—and presents them in a unified interface accessible via web, tablet, and mobile devices.
How does the team demonstrate founder-market fit?: The team slide (Slide 5) highlights that the lead founder, Mikael, has lived with Type 1 diabetes for 15 years and has 16 years of software experience. This combination of personal patient experience and technical proficiency is a strong signal to investors that the product is built to solve real-world user pain points.
What are the key milestones on the Sensotrend roadmap?: According to Slide 4, the company planned a launch in Finland in late 2014, followed by an international launch in 2015. The roadmap includes clinical trials in 2016, achieving Medical Device Certification in 2017, and moving into advanced data analytics by 2018.
What market data does Sensotrend use to justify the opportunity?: Sensotrend uses two primary sources: the IDF Diabetes Atlas 2013 for global healthcare expenditure (Slide 7) and research2guidance for the growth of the diabetes app market (Slide 8). The latter predicts the market will grow from $4.1 million to $465 million over a five-year period.
What is missing from this pitch deck?: The deck is notably missing a business model slide explaining how they charge for the service (B2B vs. B2C). It also lacks a 'The Ask' slide, meaning there is no information on how much capital they are raising or how they intend to use the funds. Finally, there is no mention of existing competitors or their specific competitive advantage.

Cover slide of the Sensotrend pitch deck — Early Stage (Demo Day) 2013 — Sensotrend pitch deck, slide 1 (2013)

Sensotrend pitch deck: the facts

Company: Sensotrend
Year: 2013/2014 (…
Stage: Early Stage (Demo Day)
Slides: 15
Sector: HealthTech / Diabetes Management
Deck type: Demo Day Pitch
Outcome: Not stated
Headquarters: Finland

Sensotrend pitch deck PDF

The full Sensotrend deck is embedded on this page and can be read slide by slide in the browser — no download or account required. Each slide is covered in the breakdown above.

What the Sensotrend pitch deck was used for

This deck is Sensotrend’s Startup Sauna Demo Day presentation from around 2013–2014, when the company was an early-stage Finnish healthtech startup focusing on an automated diabetes diary and data aggregation for people with diabetes. It framed Sensotrend as a central hub that connects glucometers, insulin pumps, continuous glucose monitors, activity trackers and meal logging apps into personal health record platforms, replacing manual diary-keeping with automated data flows. The deck was used in the Startup Sauna accelerator’s demo day to showcase the product and company rather than in a clearly documented priced funding round, and no specific fundraising amount or investors tied to this deck can be verified from external sources.

Business model: Sensotrend develops diabetes data and remote monitoring software that aggregates data from medical devices, wellness trackers and health record platforms, visualizes it for patients and clinicians, and facilitates sharing via healthcare IT integrations.

Founded: 2013
Founders: Mikael Rinnetmäki
Headquarters: Tampere, Finland
Industry: HealthTech / Digital diabetes management and health data interoperability

What happened after the Sensotrend deck

Following its early Startup Sauna demo day pitch around 2013–2014, Sensotrend has evolved from an automated diabetes diary concept into a broader remote monitoring and health data interoperability platform. It has completed incubation and acceleration programs, launched multiple products for data ingestion, visualization and care-plan management, participated in national and international FHIR-bas

Sensotrend was incubated at Protomo and accelerated at Startup Sauna, indicating successful completion of early-stage su
The company has developed a suite of products including Sensotrend Uploader, Sensotrend Connect, Sensotrend Dashboard an
Sensotrend’s solutions have been demonstrated in national and international interoperability initiatives, such as FHIR D
Public business directories indicate that Sensotrend Oy continues to operate from Tampere with active contact details, s

What the Sensotrend deck got right

Strong problem-solution alignment in diabetes management. Sensotrend addresses a well-defined and high-need problem in type 1 diabetes: the burden of manual diary-keeping and the challenge of making sense of diverse data sources, offering an automated diary and integrated dashboard as a direct solution.
Clear and consistent technical vision around data aggregation. The company’s product vision from the demo day era is tightly aligned with its later offerings—Uploader, Connect, Dashboard and CarePlan—which demonstrates execution consistency on aggregating device and wellness data into personal health records and FHIR-based infrastructures.
Differentiation through interoperability and standards-based integration. Sensotrend emphasizes interoperability, integrating with dozens of medical devices and wellness trackers and transforming data into standard formats like HL7 FHIR, which is attractive to healthcare organizations seeking vendor-agnostic remote monitoring solutions.
Emphasis on collaborative care and actionable insights. The narrative around facilitating sharing of data and insights with healthcare professionals and peers positions Sensotrend as enhancing care collaboration and peer support, which adds clinical and social value beyond simple tracking.
Credibility from incubator, accelerator and interoperability programs. Participation in recognized ecosystems—Protomo incubator, Startup Sauna accelerator, FHIR demos and IHE Plugathon—provides external validation of Sensotrend’s team and technology, strengthening the credibility of the pitch.
Alignment with national e-health infrastructure and patient data rights. Sensotrend’s focus on integrating with national infrastructures like Finland’s Kanta repository and enabling patient-generated health data downloads suggests a forward-looking approach to policy and infrastructure trends in e-health.

What could have been stronger

Limited visible traction and clinical validation in early-stage narrative. External descriptions of Sensotrend’s solution focus on technical capabilities and integration with personal health records but do not mention early clinical outcomes, usage metrics or revenue, suggesting the demo day deck likely lacked hard traction or clinical validation data at that time.
Regulatory and interoperability strategy likely under-specified. Sensotrend’s product relies on integrating data from multiple medical devices, wellness trackers and national health record infrastructures, yet early accelerator-era materials do not spell out a clear regulatory and interoperability roadmap, which could leave investor questions about compliance and integration risk.
Early deck’s go-to-market and revenue model appear opaque. The automated diabetes diary operates on personal health record platforms and interfaces with national infrastructures like Finland’s Kanta repository, but externally available information around 2013–2014 does not clearly define Sensotrend’s business model, pricing, or how it sells to healthcare organizations versus direct-to-consumer, making the early pitch’s commercialization plan harder to assess.
Unclear defensible moat beyond integrations and UX. While Sensotrend positions itself around interoperability with multiple device and app ecosystems, public profiles do not highlight unique proprietary algorithms or defensible IP, so investors reviewing the demo day deck may have struggled to see durable differentiation beyond integrations and user experience.

How an investor would read this deck

What draws attention

Strength of the **problem-solution fit** in type 1 diabetes: people with diabetes must keep detailed diaries and learn from their data, and Sensotrend offers to automate and visualize this process via an integrated dashboard and remote monitoring tools.
Evidence that Sensotrend can reliably ingest and normalize data from a wide range of devices and cloud services into personal health record systems and HL7 FHIR-based infrastructures, as later described in Sensotrend Connect’s technical documentation.
Regulatory and data-governance approach to handling medical device data, integrating with national health repositories like Kanta, and complying with privacy and security requirements for patient-generated health data.
Commercial traction with healthcare organizations, payers or national e-health initiatives, including adoption of Sensotrend Connect, CarePlan for Diabetes and related dashboards in routine clinical workflows.

Risks that stand out

Dependence on evolving data standards and third-party device APIs for glucometers, continuous glucose monitors, insulin pumps and wellness trackers, which can change or be restricted, creating integration and maintenance risk for Sensotrend’s services.
Regulatory and privacy exposure from handling sensitive medical and wellness data, especially as solutions interact with national health repositories like Kanta and patient-generated health data download services, requiring continuous compliance investment.
Competitive pressure from larger health IT vendors, device manufacturers and digital health platforms that may build similar dashboards or remote monitoring capabilities and bundle them with existing products, potentially limiting Sensotrend’s market share.
Challenges in converting strong technical capabilities and interoperability into scalable, recurring revenue if healthcare procurement cycles are slow and if the business model is not clearly defined and proven in multiple markets.

Questions this deck invites

What concrete user and clinic outcomes (e.g., reduced hypoglycemia, improved time-in-range, reduced appointment time) have been demonstrated using Sensotrend’s Automated Diabetes Diary and Connect solutions, and in what studies or pilots?
How does Sensotrend charge for its products (licenses, SaaS, per-patient, per-organization), and what has been the most successful route to market: direct sales to clinics, partnerships with health IT vendors, or national programs?
Which device manufacturers, wellness platforms and EHR vendors does Sensotrend currently integrate with, and what formal agreements or certifications (e.g., IHE, HL7 FHIR) underpin those integrations?
How does Sensotrend mitigate platform risk and ensure continuity when third-party device vendors change APIs, data formats or business models?
What is Sensotrend’s long-term defensibility: does it rely on proprietary algorithms, unique health data access (e.g., Kanta integrations) or specialized expertise that would be hard for larger health IT players to replicate?

What founders can take from the Sensotrend deck

A clear and specific **use case**—automating the diabetes diary and aggregating data from medical devices and wellness apps into a unified view—creates a compelling narrative for both patients and clinicians when framed around a well-understood chronic condition.
Positioning the company as an **interoperability and data hub** for chronic disease management can differentiate it from single-device apps, particularly when tied to emerging personal health record platforms and national e-health infrastructures.
Highlighting integration with established health IT standards (e.g., HL7 FHIR, SMART on FHIR) and national health repositories can signal technical maturity and facilitate conversations with institutional healthcare customers.
Incubation and acceleration credentials, such as participation in Protomo and Startup Sauna, can provide external validation of an early-stage startup’s concept and team when traction data is still limited.
Framing the solution around **actionable insights**—not just raw data aggregation—helps investors see clinical relevance and potential impact on treatment decisions, even at an early product stage.
Designing a product suite (Uploader, Connect, Dashboard, CarePlan) that addresses ingestion, visualization and care-path structuring illustrates how an initially narrow solution like an automated diabetes diary can evolve into a broader remote monitoring and care-management platform.

Sensotrend pitch deck: common questions

What does Sensotrend do?

Sensotrend is a Finnish healthtech company that builds software to aggregate and visualize data from diabetes devices, wellness trackers and health record platforms, making it easier for people with diabetes and their care teams to manage the condition.

What product was Sensotrend pitching in the Startup Sauna demo day deck?

Sensotrend’s main early product was an **Automated Diabetes Diary** that operates on personal health record systems, combining data from glucometers, insulin pumps, wearables and wellness apps into meaningful visualizations for diabetes treatment. More recently, its product suite includes Sensotrend Uploader and Sensotrend Connect for ingesting data from devices and cloud services, Sensotrend Dashboard for visualization, and CarePlan for Diabetes for structuring treatment protocols.

Where is Sensotrend located?

Sensotrend Oy is based in Tampere, Finland, with corporate addresses listed at Biokatu 12 and Arvo Ylpön katu 6 in local directories and company profiles.

What stage was Sensotrend at when it used this demo day pitch deck?

The deck was used at Startup Sauna’s demo day around 2013–2014, when Sensotrend was in an early acceleration/incubation phase; the company notes that it has been incubated at Protomo and accelerated at Startup Sauna. There is no externally verified information that this specific deck corresponded to a particular priced funding round or disclosed fundraising target.

Who invested in Sensotrend or how much did it raise with this deck?

Public profiles and databases describing Sensotrend focus on the product and business but do not cite any specific named investors, round sizes, valuations or dates; detailed funding information appears behind paywalls (e.g., in investor intelligence platforms) and cannot be verified from accessible sources. As a result, there is no confirmed list of investors or funding amounts directly tied to the Startup Sauna demo day deck.